AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03010488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morning Light Therapy
Description: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
Study NCT03010488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morning Light Therapy
Description: 10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
Study NCT03010488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assigned Sleep Times
Description: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
Study NCT03010488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned Sleep Times
Description: Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
Study NCT03010488 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goggles
Description: Subjects will wear goggles during saliva collection and Bright Light Therapy
Study NCT03010488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goggles
Description: Subjects will wear goggles during saliva collection and Bright Light Therapy
Study NCT02713074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine
Description: The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
Study NCT02713074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
Study NCT04129437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Weight based ibuprofen dosing
Study NCT04129437 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic manipulative treatment
Description: Low velocity osteopathic manipulative treatment
Study NCT03264053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Socket shield
Description: Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
Study NCT03264053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional immediate implantation
Description: Conventional immediate implantation
Study NCT01737593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT03956537 — intervention group
Intervention type: DEVICE
Intervention: NEO Pedicle Screw System™
Description: The NEO Pedicle Screw System™ is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion.
Study NCT03956537 — intervention group
Intervention type: DEVICE
Intervention: Neo Cage System™
Description: Neo Cage System™ is intended to be used with bone graft material to facilitate interbody fusion and to be used with the NEO Pedicle Screw System™
Study NCT01713101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early intravenous tranexamic acid administration
Description: Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
Study NCT01713101 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colistin and imipenem
Description: colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colistin  and imipenem .
Description: colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colimycin (colistin)
Description: nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colimycin (colistin)
Description: intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Oral JAK inhibitor
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ruxolitinib
Description: Oral JAK inhibitor
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: glucocorticoid
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: glucocorticoid
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS colistin and imipenem
Description: IV imipenem 1 g three times per day.
Study NCT02683603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV colistin and imipenem
Description: IV imipenem 1 g three times per day
Study NCT01666340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: Group asked to perform exercise at a given moderate intensity for a set time
Study NCT01666340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: Group asked to perform exercise at a given moderate intensity for a set time
Study NCT01666340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise intervention
Description: High intensity exercise
Study NCT01666340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: High intensity exercise
Study NCT01788436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 1
Description: The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
Study NCT01788436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Test Battery 1
Description: The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
Study NCT01788436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Test Battery 2
Description: The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
Study NCT01788436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Test Battery 2
Description: The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
Study NCT03464292 — intervention group
Intervention type: DRUG
Intervention: Capsaicin Patch 8% or 0.1% Capsaicin Cream
Description: 0.1 ml of 8% capsaicin topical patch or 0.1% capsaicin cream
Study NCT03464292 — intervention group
Intervention type: OTHER
Intervention: Vehicle Patch
Description: Control patch will be the same topical solution but will not contain capsaicin.
Study NCT04028271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comfort-in injection system
Description: local anesthesia during dental treatment
Study NCT04028271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional injection with dental needle
Description: for local anesthesia during dental treatment
Study NCT01734889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone
Description: Oral suspension
Study NCT02842034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks.
Study NCT03757104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIC-HIV
Description: Men in these communities are eligible to receive a tablet-based male-sensitive HIV decision support app (EPIC-HIV 1)to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
Study NCT03757104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: micro-incentive and EPIC-HIV
Description: micro-incentives: Residents in these communities are eligible to receive a R50 food voucher conditional on undergoing a home-based HIV test. If diagnosed with HIV, residents are eligible to receive a second R50 food voucher when they link to care within 6 weeks of the HIV test.~EPIC-HIV 1:~Men in these communities are eligible to receive a tablet-based male-sensitive HIV specific decision support app (EPIC-HIV 1) to encourage them to test for HIV at home. If diagnosed with HIV and do not link to care within a month of HIV test, they become eligible to receive a tablet-based male HIV specific decision support app (EPIC-HIV 2) to encourage them to link to HIV care.
Study NCT01431404 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept (Enbrel)
Description: prefilled syringe, SC
Study NCT01431404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HD203
Description: HD203, prefilled syringe, SC injection
Study NCT01211379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLU-FOBT Program
Description: Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
Study NCT02842034 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Stimulate the dorsomedial prefrontal cortex for 4 weeks.
Study NCT02598765 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trabeculectomy
Description: Fornix-based trabeculectomy with a 3x4 mm scleral flap.
Study NCT02598765 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microtrabeculectomy
Description: Fornix-based trabeculectomy with a 2x2 mm scleral flap.
Study NCT01865331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Single dose administered subcutaneously (s.c., under the skin).
Study NCT01865331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin)
Study NCT01865331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart 50
Description: Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
Study NCT04999579 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T scan
Description: Occlusal load analysis
Study NCT04999579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T scan
Description: Occlusal load analysis
Study NCT01397578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating subcutaneous injection
Study NCT01397578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: Repeating intravenous infusion
Study NCT01397578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating subcutaneous injection
Study NCT01397578 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Repeating intravenous infusion
Study NCT02338102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline mixture
Description: premeasured salt packets mixed with distilled water
Study NCT03356184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Rhea Vital Sign Vigilance Device Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03356184 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Earlysense System Device Group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT04102969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benson Relaxation Technique
Description: Benson relaxation technique will be performed two times a day for 10 minutes during the study period ( two months) for the intervention group.
Study NCT04102969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Package Session
Description: A nutrition package session will be given to the control group.
Study NCT01113970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indibulin
Description: Indibulin given orally once a day for 5 days followed by a 9 day rest
Study NCT02576314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sofosbuvir and daclatasvir
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
Study NCT02576314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ledipasvir/sofosbuvir
Description: Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.~once daily;
Study NCT02721537 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Three capsules, twice per day for 84 days
Study NCT02721537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Three matching capsules, twice per day for 84 days
Study NCT01583374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast tablet 20 mg
Description: Apremilast 20 mg was taken orally twice a day (BID)
Study NCT01583374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast tablet 30 mg BID
Description: Apremilast 30 mg was taken orally twice a day
Study NCT01583374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Study NCT02263352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day
Description: Lycopene 8mgms taken orally ,one per day for two months.
Study NCT02263352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
Study NCT03661567 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest radiation
Description: split-course chest radiation
Study NCT03661567 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chest radiation
Description: split-course chest radiation
Study NCT00460343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: extensive implementation programme
Description: experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
Study NCT00460343 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
Study NCT02254031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine
Study NCT01986062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR11
Study NCT01986062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02482584 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP intervention
Study NCT02482584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Control
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination
Description: Novel dry powder inhaler
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination
Description: Novel dry powder inhaler
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Inhaler
Description: Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Film coated oral tablet
Study NCT01209026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Film coated oral tablet
Study NCT03661567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study NCT03661567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concurrent chemotherapy
Description: weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
Study NCT03661567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone after the first course of radiation, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
Study NCT03260049 — intervention group
Intervention type: PROCEDURE
Intervention: pars plana vitrectomy
Description: pars plana vitrectomy
Study NCT04170972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: One hour of acute one-legged knee-extensor exercise followed by 3 hours recovery and 2 hours insulin (1.5 mU/min/kg) stimulation.
Study NCT00003590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: 20 mg/kg/day PO
Study NCT02463890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Study NCT02463890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Study NCT03463005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Royal jelly
Description: The study subjects in the Royal jelly group used 10 ml of the vaginal Royal jell few minutes before and few minutes after intercourse one day after the end of menstruation for two weeks.
Study NCT03463005 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IUI
Description: Subjects in IUI group received 75 units of FSH from the second day of the cycle.
Study NCT01131819 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nintendo Wii fit ™ balance board
Description: Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
Study NCT01491113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 250 mg
Description: Tablet containing Levetiracetam 250 mg
Study NCT01491113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 500 mg
Description: Tablet containing Levetiracetam 500 mg
Study NCT02980809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study NCT02980809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study NCT02980809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Study NCT01810614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADPKD Diet
Description: Diet specifically designed for people with ADPKD
Study NCT04620213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Ophthalmic Solution 0.75%
Description: 0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist